Clinical trial
An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)
Name
HSC20200720H
Description
Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.
Trial arms
Trial start
2021-04-28
Estimated PCD
2022-04-15
Trial end
2022-04-15
Status
Completed
Phase
Early phase I
Treatment
Rapamycin Topical Ointment
8% topical rapamycin ointment
Arms:
Topical Rapamycin
Other names:
Sirolimus Topical Ointment, RAPA Topical Ointment
Placebo
Petrolatum ointment containing no active ingredient
Arms:
Placebo
Other names:
Placebo Topical Ointment, Petrolatum
Size
22
Primary endpoint
Change in Epigenetic Markers
Baseline to 6 months
Eligibility criteria
Inclusion Criteria:
* 65-95 years of age.
* Good health with all chronic diseases (hypertension, coronary artery disease, etc.) clinically stable.
* Selected subjects will be in good health (Per the World Health Organization, good health will be defined as complete physical, mental, and social well-being and not merely the absence of disease or infirmity).
* All diseases or infirmities will be clinically stable whether managed by medications or not.
* CLOX score of 10 or greater
* Women will be postmenopausal
* Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for ≥6 months
* Live within a 20 mile drive of the UTHSA campus (7703 Floyd Curl Drive, San Antonio, TX)
Exclusion Criteria:
* Diabetes.
* History of skin ulcers or poor wound healing, or keloid formers.
* Smoking.
* Liver disease.
* Coumadin anti-coagulation.
* Treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin, etc. - due to role in rapamycin metabolism).
* Treatment with an immunosuppressant (prednisone, etc.) within 6 months.
* History of recent (within 6 months) Myocardial Infarction or active Coronary Disease.
* Hypersensitivity to rapamycin or petrolatum (ointment vehicle)
* Arm tattoos or scars in application area
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants will be their own control, either right or left arm will be randomized to treatment or placebo.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'Randomization will be performed by the compounding pharmacy. Ointment dispensers will be color-coded for left and right arm for each subject.', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}
Updated at
2023-07-19
1 organization
1 product
3 indications
Product
RapamycinIndication
AgingIndication
EpigeneticsIndication
Inflammatory Mediators